

Phase I Clinical Trial for Advanced Colon and Pancreatic Cancer Opens in New York Using Regin-G, the World's First Tumor-Targeted Gene Delivery Vector

LOS ANGELES, Calif. – (SEND2PRESS NEWSWIRE) – Epeius Biotechnologies Corporation (www.epeiusbiotech.com) announced today that a Phase I clinical trial has opened in New York to test the safety and efficacy of Regin-G, the leading tumor-targeted gene delivery system (vector) developed for the treatment of metastatic colon and pancreatic cancer.

In 2003, Regin-G gained FDA approval as an Orphan Drug based on clinical demonstrations of the medical utility of Regin-G as an effective treatment for pancreatic cancer.

Six out of six initial patients with advanced pancreatic cancer responded favorably to Regin-G, as evidenced by significant shrinkage and/or disappearance of metastatic tumor nodules, or stabilization of disease, relief from pain, weight gain and extension of over-all survival time, without experiencing the side effects generally associated with standard chemotherapy. Clinical trials of Regin-G have now been expanded to include patients with colorectal cancer that has spread to the liver.

Epeius Biotechnologies Corporation recently secured exclusive licensing rights to its Pathotropic (disease-seeking) targeting platform, including the FDA-approved Targeted Delivery System (TDS) that enables its lead product, Regin-G, to seek and destroy metastatic tumors. Following the success of "compassionate use" clinical trials using Regin-G for metastatic pancreatic cancer, Epeius Biotechnologies has completed the transition from an academic start-up to a specialty pharmaceutical company, and has gained the financial support needed to expand the scope of its landmark clinical trials in the United States.

In a statement to the press, Dr. Frederick Hall, President and CEO of Epeius said that, "We are now in an excellent position to complete our mission: to develop our business plan in an exemplary manner, and to commercialize our high-value lead product for the benefit of cancer patients worldwide."

About Epeius

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company that was formed to develop and commercialize the first truly effective Targeted Delivery System (TDS) that can be injected directly into a vein to deliver genetic medicine preferentially to cancerous tumors that have spread throughout the body (metastatic cancer), without eliciting systemic

side effects or organ damage.

More information: www.epeiusbiotech.com.

News issued by: Epeius Biotechnologies Corporation

#

Original Story ID: (237) :: 2005-04-0405-001

Original Keywords: Epeius Biotechnologies Corporation, Rexin-G, Rexin G, Dr. Frederick L. Hall, clinical trial, FDA approval, Orphan Drug, tumor-targeted gene delivery system, vector, metastatic tumor nodules, advanced pancreatic cancer, new york news, Targeted Delivery System (TDS), biotech newswire, biotechnology, medtech Epeius Biotechnologies Corporation